<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00788112</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000617655</org_study_id>
    <secondary_id>UCSF-077532</secondary_id>
    <secondary_id>H10367-31833</secondary_id>
    <secondary_id>UCSF-07031833</secondary_id>
    <nct_id>NCT00788112</nct_id>
  </id_info>
  <brief_title>Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast</brief_title>
  <official_title>A Window Trial of Vorinostat in Patients With Ductal Carcinoma in Situ (DCIS) of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well vorinostat works in treating women with&#xD;
      ductal carcinoma in situ of the breast.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the in vivo molecular and biological effects of vorinostat by analyzing&#xD;
           changes in proliferation and apoptosis, histone acetylation, and HDAC protein expression&#xD;
           in women with ductal carcinoma in situ of the breast.&#xD;
&#xD;
      OUTLINE: Patients receive oral vorinostat twice a day for 3 days in the absence of&#xD;
      unacceptable toxicity. Patients then undergo lumpectomy or mastectomy 2 hours after the last&#xD;
      dose of vorinostat.&#xD;
&#xD;
      Blood and tissue samples are collected at baseline and during surgery for biomarker&#xD;
      laboratory studies. Samples are analyzed by immunohistochemistry for Ki-67, HDAC1 and HDAC6&#xD;
      protein expression, and histone H4 and α-tubulin acetylation.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 1 month and then every 6 months&#xD;
      for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">August 11, 2015</completion_date>
  <primary_completion_date type="Actual">November 3, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Ki-67 compared to baseline Ki-67</measure>
    <time_frame>3 days prior to surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in HDAC1 and HDAC6 expression and histone H4 and α-tubulin acetylation in breast tissue and serum samples</measure>
    <time_frame>3 days prior to surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein expression analysis</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <arm_group_label>Vorinostat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed (by core biopsy) ductal carcinoma in situ&#xD;
&#xD;
               -  Stage 0 disease&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Potassium and magnesium levels normal&#xD;
&#xD;
          -  Prothrombin time or INR ≤ 1.5 times upper limit of normal (ULN) (unless the patient is&#xD;
             receiving therapeutic anticoagulation)&#xD;
&#xD;
          -  Partial thromboplastin time ≤ 1.2 times ULN (unless the patient is receiving&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use 2 effective barrier methods of contraception&#xD;
&#xD;
          -  No known psychiatric or substance abuse disorder that would preclude cooperation with&#xD;
             the study requirements&#xD;
&#xD;
          -  No active hepatitis A, B, or C infection&#xD;
&#xD;
          -  No active HIV infection&#xD;
&#xD;
          -  No other active infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years&#xD;
&#xD;
          -  No condition that would interfere with the absorption or intake of vorinostat&#xD;
&#xD;
          -  No history or current evidence of any condition or laboratory abnormality that would&#xD;
             confound study results, interfere with the patient's participation in the full&#xD;
             duration of the study, or that would not be in the best interest of the patient to&#xD;
             participate&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 2 weeks since prior IV antibiotics, antivirals, or antifungals&#xD;
&#xD;
          -  No prior gastrointestinal surgery or other procedure that would interfere with the&#xD;
             absorption or intake of vorinostat&#xD;
&#xD;
          -  No prior or concurrent therapy with any other HDAC inhibitor, including valproic acid&#xD;
&#xD;
          -  No prior treatment with any other investigational agent&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy, radiotherapy, biological therapy, or other&#xD;
             investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Esserman, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>November 7, 2008</study_first_submitted>
  <study_first_submitted_qc>November 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2008</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Intraductal, Noninfiltrating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

